We provide you with 20 years of free, institutional-grade data for ATNM stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ATNM. Explore the full financial landscape of ATNM stock.
| Reported Date | CIK | Ticker | Type |
|---|
Actinium Pharmaceuticals, Inc(NYSE MKT:ATNM) 
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a ...
The information provided in this report about ATNM stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.